Brainstorm Cell Therapeutics ( (BCLI) ) has released its Q4 earnings. Here is a breakdown of the information Brainstorm Cell Therapeutics presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BrainStorm Cell Therapeutics Inc. is a pioneering company in the biotechnology sector, focusing on the development of autologous adult stem cell therapies for neurodegenerative diseases, with a notable emphasis on amyotrophic lateral sclerosis (ALS).